

B1
fos;
jun; and
a promoter comprising an AP-1 site that regulates expression of a first reporter gene;
b) contacting said first cell with said transcription factor ligand and with a compound having AP-1 mediated estrogenic activity; and
c) detecting expression of said first reporter gene, whereby an alteration in expression of said first reporter gene, as compared to expression of said first reporter gene in the absence of said transcription factor ligand, indicates that said nuclear transcription factor ligand modulates estrogen activation at an AP-1 site.

B2
10. The method of claim 1, wherein said cell expresses said fos or said jun from a heterologous DNA.

11. The method of claim 10, wherein said AP-1 protein said fos or said jun is c-jun.

These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter or agreement with the Examiner's position. In accordance with the requirements of 37 C.F.R. § 1.121, a marked up version showing the changes to the claims, is attached herewith as Appendix A. For the Examiner's convenience, a complete claim set of the currently pending claims is also submitted herewith as Appendix B.

REMARKS

Status of the Claims.

Claims 1-13 are pending with entry of this amendment, claims no claims being cancelled and no claims being added herein. Claims 1, 10, and 11 are amended herein. These amendments introduce no new matter. Support is replete throughout the specification (e.g., claims 10 and 11 as filed, the specification page 15, lines 11-20, page 10, lines 3-13, and the like).